drugset / Trial / NCT01522872
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2012-02
- Primary completion
- 2016-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Evofosfamide | Other / unclassified | — | — |
| Subject | Pomalidomide | Other / unclassified | — | — |